Roest et al 1 reported a nested case-control study that assessed the relation between 4G/5G polymorphism in the plasminogen activator inhibitor (PAI-1) gene and cardiovascular and cerebrovascular mortality in women. The authors found that 4G/4G homozygotes had a decreased risk of dying from stroke compared with 5G/5G homozygotes (relative risk, 0.4; 95% confidence interval [CI], 0.2 to 0.7); the relative risk was 0.7 (95% CI, 0.4 to 1.1) for 4G/5G heterozygotes.
Response
The findings by Elbaz et al confirm our observations. 1 Moreover, a comparable but nonsignificant reduced stroke incidence in relation to the plasminogen activator inhibitor (PAI-1) 4G polymorphism was reported previously by Catto et al. 2 In a pooled analysis of the results of all published studies on the relationship between PAI-1 4G5G genotype and stroke, the genotype distribution in stroke incidence cases is as follows: 4G4G, 296 (26.1%); 4G5G, 559 (49.3%); and 5G5G, 278 (24.5%). The distribution in controls is as follows: 4G4G, 344 (30.1%); 4G5G, 587 (51.3%); and 5G5G, 213 (18.6%). Using 5G5G as the reference group, the odds ratios are 0.66 (95% CI, 0.52 to 0.84) for 4G4G homozygotes and 0.73 (95% CI, 0.59 to 0.90) for 4G5G heterozygotes. The findings of this pooled analysis are suggestive of a protective role of plasminogen activation inhibition in cerebrovascular morbidity and mortality.
The 4G polymorphism is located in the promoter region of the PAI-1 gene and is responsible for increased transcription of PAI-1 and increased production of PAI-1. PAI-1 is a major inhibitor of plasminogen activation to plasmin via the binding of tissue-type plasminogen activator and urokinase-type plasminogen activator. Therefore, the PAI-1 4G polymorphism may lead to reduced plasminogen activation to plasmin.
Until recently, it was believed that PAI-1 was a potential predictor of an increased risk of cerebrovascular disease via the inhibition of fibrinolysis. The findings that the PAI-1 4G polymorphism is related to a reduced risk of cerebrovascular disease argues against this view. Further evidence against this hypothesis comes from findings that plasma levels of tissue-type plasminogen activator are an independent risk factor for cerebrovascular disease 3 and the fact that PAI-1 levels are not independently associated with stroke incidence. 4 The mechanism that relates plasminogen activation to cerebrovascular disease probably reflects a nonfibrinolytic function of plasmin. Increased plasminogen activation may lead to increased laminin degradation in extracellular brain tissue and, hence, a reduced resistance of the brain against both ischemic and hemorrhagic damage. 5 on behalf of the GÉNIC investigators; Alexis Elbaz, François Cambien and Pierre Amarenco
